(HealthDay News) — For patients with papulopustular rosacea (PPR), once-daily ivermectin 1% cream (IVM 1%) is superior to twice-daily metronidazole (MTZ 0.75%) cream, according to a study published in the April issue of the British Journal of Dermatology.
Alain Taieb, MD, PhD, from Hôpital Saint-André in Bordeaux, France, and colleagues conducted a phase 3 randomized trial involving patients with PPR. Participants were randomized to receive once-daily IVM 1% cream (478 participants) or twice-daily MTZ 0.75% cream (484 participants) for 16 weeks. Inflammatory lesion counts and Investigator’s Global Assessment (IGA) were used to assess efficacy.
The researchers found that IVM 1% was significantly superior to MTZ 0.75% at week 16 in terms of reduction in inflammatory lesions from baseline (83.0 vs. 73.7%; P<0.001). This superiority was observed as early as week three. IVM 1% was also superior in terms of IGA results (subjects ‘clear’ or ‘almost clear’) (84.9 vs. 75.4%; P<0.001). Comparable adverse event incidence was seen between the groups; local tolerability was superior for IVM 1%. Global improvement was rated as ‘excellent’ or ‘good’ by more patients receiving IVM.
“In conclusion, while MTZ 0.75% cream has been the standard treatment for the papulopustular lesions of rosacea, its efficacy is now surpassed by that of IVM along with the advantage of once-daily dosing and high patient satisfaction,” the authors write.
Two authors disclosed financial ties to Galderma R&D, which manufactures ivermectin and funded the study.